企業プロフィール
Relay Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- RLAY
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
20.67 USD (+4.08%)
終値
最終更新: 2026年8月17日
3.42B USD
時価総額
株価変動の要因
As of Aug 17, 2026, RLAY closed up 4.08% at $20.67. No new same-company headline was identified in the current news window.
企業概要
Structure-Based Precision Medicine
Relay Therapeutics develops small-molecule medicines using a platform designed to model protein motion and identify druggable conformations. Its clinical portfolio focuses on genetically defined cancers and diseases driven by difficult-to-target proteins.
Zovegalisib in Breast Cancer
Zovegalisib is a mutant-selective PI3Kα inhibitor intended to preserve activity against oncogenic PIK3CA mutations while limiting inhibition of wild-type PI3Kα. It is being evaluated with fulvestrant in the Phase 3 ReDiscover-2 trial for previously treated HR-positive, HER2-negative advanced breast cancer.
Frontline Combination Strategy
Relay selected zovegalisib with atirmociclib and endocrine therapy as its preferred triplet for first-line endocrine-sensitive metastatic breast cancer. The approach combines selective PI3Kα and CDK4 inhibition while Relay retains global rights to zovegalisib.
Vascular Anomalies
Because activating PI3Kα mutations also drive many vascular anomalies, Relay is evaluating zovegalisib outside oncology. This program broadens the addressable population for the molecule and tests its mutant-selective profile in a genetic disease setting.
NRAS Program
RLY-8161 is an NRAS-selective molecule in Phase 1/2 development for NRAS-mutant solid tumors. The program adds a second clinically tested precision-oncology mechanism to Relay’s pipeline.
今後のカタリスト
- Initial zovegalisib clinical data in vascular anomalies expected at the ISSVA meeting.
- Initiation of a Phase 3 first-line breast-cancer trial of zovegalisib, atirmociclib and endocrine therapy expected in early 2027, subject to regulatory feedback.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。